 | This articlemay need to be rewritten to comply with Wikipedia'squality standards.You can help. Thetalk page may contain suggestions.(January 2022) |
 | This article needs to beupdated. Please help update this article to reflect recent events or newly available information.(January 2022) |
_2021_cropped.jpg) Oxford–AstraZeneca (Covishied), the most commonly used vaccine in Nepal[1] | |
| Date | 27 January 2021 (2021-01-27) – present (4 years, 269 days ago) |
|---|---|
| Location | Nepal |
| Cause | COVID-19 pandemic in Nepal |
| Target | Immunisation of Nepalese against COVID-19 |
| Organised by | Government of Nepal |
| Participants |
|
| Outcome |
|
| Website | www vaccine |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
Nepal began administration ofCOVID-19 vaccines on 27 January 2021. 1 millionOxford-Astrazeneca vaccines were provided byIndia as a grant while Nepal brought 2 million doses fromSerum Institute of India (SII) and was one of the first to receive COVID-19 vaccines. The delivery of the first 1 million doses arrived on 21 February.[2] In March, India's decision to ban exports of vaccines created uncertainty over whether Nepal would be able to continue its vaccinations. By April, SII had only provided half of the 2 million doses for which Nepal had paid in full. A spokesperson for the Indian Ministry of External Affairs rejected the notion of an export ban and said "We will export vaccines taking into account the domestic demand."[3] By late July, there was still uncertainty in Nepal over when SII would deliver the vaccines that were purchased, althoughPrime Minister Narendra Modi said India would "resume the supply of vaccines soon."[4]
Nepal approvedChina'sSinopharm BIBP vaccine (BBIBP-CorV) for emergency use on 15 February. The first doses arrived in Nepal on 29 March.[2] By July, China, had provided 1.8 million doses of the Sinopharm BIBP vaccine under grant assistance, and committed to providing another 1.6 million doses. Separately, the government purchased 4 million doses in June for which delivery was expected to be complete in a few days and was expected to purchase another 6 million doses in July.[5]
About 1.52 million doses of single doseJanssen vaccine (Johnson & Johnson) arrived on July as aid from theUnited States.[6] Similarly, AmbassadorBerry assured that the U.S. had prioritized additional vaccine assistance to Nepal realizing the need.[7] Nepal on 25 October 2021 received 100,620 doses of Pfizer-BioNtech COVID-19 vaccine provided by the United States throughCOVAX.[8]
Nepal is set to receive 1.6 million doses of single doseOxford AstraZeneca as aid from Japan.[9] Nepal has requested additional 3 lakhs vaccine dosage fromBhutan which is under consideration.[10]
The campaign was launched with the 1 million doses initial doses of the Oxford-Astrazeneca vaccine. At that time, the virus had claimed 2,017 lives and infected 270,092 across the country. Around 430,000 frontline workers–health workers, supporting staffers at health facilities, female community health volunteers, security personnel, sanitation workers, elderly people living in care homes, and prisoners–were listed as priority groups for vaccination. After the first round of the first phase was completed, the government said journalists and diplomatic staff could take the jabs. When the government announced that the first phase was completed on 5 March, as many as 438,000 had received their first dose.[2]
The day the second phase of vaccination was started 348,000 doses of Covishield arrived in Nepal under the World Health Organization-backed COVAX facility. The government said all the citizens above 65 years of age would be inoculated. The public response was quite encouraging. In the second phase, around 1.3 million people were inoculated across the country.[11]
Nepal became the first country in the Asia Pacific to provide vaccines to the refugees. It was started in March 2021.[12]
Currently, the vaccines approved by government of Nepal for emergency use are:
| Vaccine | Country of manufacture | Approval | Deployment | Vaccination status | |
|---|---|---|---|---|---|
| First dose | Fully vaccinated | ||||
| Oxford–AstraZeneca |
|  Yes[13] | Yes | 18,68,425 | 7,24,992 |
| Janssen | USA | Yes[14] | Yes | 12,62,918[15] | |
| Sinopharm BIBP | China | Yes[16] | Yes | 25,74,537 | 7,38,324 |
| Pfizer–BioNTech | USA | Yes[17] | Yes | ||
| Moderna COVID-19 vaccine | USA | Yes[18] | Yes | ||
| Covaxin | India | Yes[19] |  No | ||
| Sputnik V | Russia | Yes[20] | No | ||
| CoronaVac | China | Yes[21] | No | ||
